TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2844031

Group type: EXPERIMENTAL
Intervention: HSV vaccine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 28893496

Group type: EXPERIMENTAL
Intervention: Moist hot pack (MHP) for 15 minutes during therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Therapeutic whirlpool bath (WB) for 15 minutes during therapy
Number of subjects: 60
Study: 27522105

Group type: EXPERIMENTAL
Intervention: Trima Accel cell separator
Number of subjects: 110
Study: 25106447

Group type: EXPERIMENTAL
Intervention: Co-careldopa treatment in addition to routine NHS occupational and physical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment in addition to routine NHS occupational and physical therapy
Number of subjects: 0
Study: 23432657

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap with connective tissue graft (CAF+CTG)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (CAF)
Number of subjects: 37
Study: 19926182

Group type: EXPERIMENTAL
Intervention: Nasal septal cartilage graft
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conchal cartilage graft
Number of subjects: 22
Study: 17595175

Group type: EXPERIMENTAL
Intervention: Immediate incentives ($5 weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed incentives ($5 at program end)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Media recruitment method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-media recruitment method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 0
Study: 17243432

Group type: EXPERIMENTAL
Intervention: Tretinoin microsphere gel 0.1%
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 11850090

Group type: EXPERIMENTAL
Intervention: Caffeine placebo
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Double blind condition
Number of subjects: 159
Study: 9602959

Group type: EXPERIMENTAL
Intervention: Ibuprofen 50 mg
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Ibuprofen 100 mg
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Rescue medication (Acetaminophen 500 mg)
Number of subjects: 304
Study: 8027413

Group type: EXPERIMENTAL
Intervention: Bupropion (225 to 450 mg/day)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Trazodone (150 to 400 mg/day)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 124

Group type: COMPARATOR
Intervention: Trazodone
Number of subjects: 124
Study: 2660893

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study: 4851085

Group type: EXPERIMENTAL
Intervention: MOPP treatment plus bleomycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: MOPP treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MOPP treatment (maintained group for 24 months)
Number of subjects: 0
Study: 30676666

Group type: EXPERIMENTAL
Intervention: 10-20-30 training concept (n=12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: sprint interval training (SIT, n=10; work/rest ratio: 6-s/54-s)
Number of subjects: 22

Group type: COMPARATOR
Intervention: sprint interval training (SIT)
Number of subjects: 22
Study: 28177725

Group type: EXPERIMENTAL
Intervention: Phosphatidic acid (PA) supplementation (750 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 15
Study: 23999311

Group type: EXPERIMENTAL
Intervention: HIGH (2×10‐15 repetitions at 80% of one repetition maximum (1RM))
Number of subjects: 56

Group type: COMPARATOR
Intervention: LOW (1×80‐100 repetitions at 20% of 1RM)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: LOW+ (1×60 repetitions at 20% of 1RM, followed by 1×10‐20 repetitions at 40% of 1RM)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: HIGH
Number of subjects: 56
Study: 21419542

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 26

Group type: COMPARATOR
Intervention: Rotatory osteotomy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Piezosurgery and Rotatory osteotomy
Number of subjects: 26
Study: 19640521

Group type: EXPERIMENTAL
Intervention: Alimaxx-E stent placement
Number of subjects: 45

Group type: COMPARATOR
Intervention: Alimaxx-E stent placement over endoscope
Number of subjects: 45
Study: 18341817

Group type: EXPERIMENTAL
Intervention: Cypher stents
Number of subjects: 8190

Group type: EXPERIMENTAL
Intervention: TAXUS stents
Number of subjects: 8190

Group type: EXPERIMENTAL
Intervention: Firebird stents
Number of subjects: 8190
Study: 15531538

Group type: EXPERIMENTAL
Intervention: Gonadotropin-stimulated COH cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural cycles
Number of subjects: 0
Study: 11376826

Group type: EXPERIMENTAL
Intervention: QRS duration <0.09 s
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: QRS duration between 0.09 and 0.11 s
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: QRS duration >0.11 s
Number of subjects: 1100
Study: 9535996

Group type: EXPERIMENTAL
Intervention: LAAM 20 mg/70 kg i.v.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: LAAM 40 mg/70 kg i.v.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: LAAM 20 mg/70 kg p.o.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: LAAM 40 mg/70 kg p.o.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8070500

Group type: EXPERIMENTAL
Intervention: U-62066E
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: U-62066E with high dose naloxone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: U-62066E with low dose naloxone
Number of subjects: 10
Study: 2653893

Group type: EXPERIMENTAL
Intervention: gemeprost 1 mg vaginal pessaries at 3 hours intervals up to a maximum of 5 mg
Number of subjects: 152

Group type: COMPARATOR
Intervention: PGF2 alpha 40 mg intra-amniotic dose
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: gemeprost
Number of subjects: 152

Group type: COMPARATOR
Intervention: PGF2 alpha
Number of subjects: 152
Study: 1091343

Group type: EXPERIMENTAL
Intervention: Vitamin C (sustained-release capsule and regular tablet)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 622
Study: 30566602

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H5N1 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unadjuvanted H5N1 vaccine
Number of subjects: 0
Study: 29911772

Group type: EXPERIMENTAL
Intervention: 5% minoxidil solution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5% minoxidil milky lotion
Number of subjects: 20
Study: 24588955

Group type: EXPERIMENTAL
Intervention: Five-layer silicone bordered dressings (Mepilex Border Sacrum(®) and 3 layer Mepilex Heel(®) dressings by Mölnlycke Health Care)
Number of subjects: 0
Study: 23291775

Group type: EXPERIMENTAL
Intervention: Essence of chicken
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 20852438

Group type: EXPERIMENTAL
Intervention: Brimonidine bid (twice daily)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Brimonidine tid (three times daily)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Brimonidine bid and tid
Number of subjects: 75
Study: 19839220

Group type: EXPERIMENTAL
Intervention: Acupuncture for chronic low back pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture for osteoarthritis of the knee
Number of subjects: 0
Study: 16938692

Group type: EXPERIMENTAL
Intervention: Interruption condition (sentences interleaved)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous condition (one passage before the other)
Number of subjects: 0
Study: 16873967

Group type: EXPERIMENTAL
Intervention: Therapeutic manipulations designed to increase cerebral metabolic rate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cerebral metabolic rate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Synaptic marker (synaptophysin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Markers for cholinergic neurons
Number of subjects: 0
Study: 12767648

Group type: EXPERIMENTAL
Intervention: Rhythm-control
Number of subjects: 200

Group type: COMPARATOR
Intervention: Rate-control
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 200
Study: 10418209

Group type: EXPERIMENTAL
Intervention: Felodipine ER (5-10 mg once daily, doubled if necessary)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Diltiazem SR (90-180 mg once daily, doubled if necessary)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Felodipine ER and Diltiazem SR
Number of subjects: 70
Study: 7592246

Group type: EXPERIMENTAL
Intervention: Diskus inhaler (salmeterol 50 micrograms twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diskhaler inhaler (salmeterol 50 micrograms twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diskus inhaler
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diskhaler inhaler
Number of subjects: 0
Study: 2087855

Group type: EXPERIMENTAL
Intervention: Nisoldipine 0.3 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 344087

Group type: EXPERIMENTAL
Intervention: Syn-Ergel
Number of subjects: 92

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 92
Study: 30832580

Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 28027338

Group type: EXPERIMENTAL
Intervention: ImPACT intervention
Number of subjects: 583

Group type: COMPARATOR
Intervention: PACT control
Number of subjects: 583
Study: 26053137

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) for quantification of abdominal SC and PP adipose tissue
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 162
Study: 23223103

Group type: EXPERIMENTAL
Intervention: Episure™ AutoDetect™ syringe
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional glass syringe
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Episure™ AutoDetect™ syringe (when used first)
Number of subjects: 14
Study: 21660300

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg once daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 μg twice daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 18977381

Group type: EXPERIMENTAL
Intervention: Sine-wave masking
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Notched-noise masking
Number of subjects: 2
Study: 16399266

Group type: EXPERIMENTAL
Intervention: Natural frequencies presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probabilities presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural frequencies presentation (sixth graders)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of children's responses
Number of subjects: 0
Study: 15528910

Group type: EXPERIMENTAL
Intervention: Sugar-free gum containing 18.8 mg of CPP-ACP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sugar-free gum not containing CPP-ACP (control)
Number of subjects: 0
Study: 10976355

Group type: EXPERIMENTAL
Intervention: Returning gastric residual volumes
Number of subjects: 35

Group type: COMPARATOR
Intervention: Discarding gastric residual volumes
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study: 9488234

Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg per day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8162007

Group type: EXPERIMENTAL
Intervention: Regimen A (1 g/d for 2 weeks followed by 1.5 g/d)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Regimen B (0.5 g/d for 1 month, 0.750 g/d during the second month, then 1 g/d)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Regimen A
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Regimen B
Number of subjects: 61

Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 61
Study: 3096633

Group type: EXPERIMENTAL
Intervention: 50 mcg ethinyl estradiol and 1.0 mg ethynodiol diacetate (EED)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 50 mcg ethinyl estradiol and 1.0 mg norethindrone acetate (ENA)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 50 mcg ethinyl estradiol and 0.5 mg d‐1 norgestrel (ENG)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (self-selected group of 50 women using alternative means of contraception)
Number of subjects: 136
Study: 30422157

Group type: EXPERIMENTAL
Intervention: Donor corneas with diabetes
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Donor corneas without diabetes
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Recipient diagnosis of PACE
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Recipient diagnosis of Fuchs dystrophy
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Operative complications
Number of subjects: 1090

Group type: COMPARATOR
Intervention: No operative complications
Number of subjects: 1090
Study: 28521782

Group type: EXPERIMENTAL
Intervention: Clinical decision support system (CDSS) for risky alcohol use intervention
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control CDSS (not specified)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: NRT combined with CDSS intervention
Number of subjects: 221
Study: 26134827

Group type: EXPERIMENTAL
Intervention: Clinical evaluation
Number of subjects: 2612

Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled food challenge
Number of subjects: 2612

Group type: COMPARATOR
Intervention: Reported data
Number of subjects: 2612

Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 2612
Study: 24241365

Group type: EXPERIMENTAL
Intervention: Post-dilution OL-HDF
Number of subjects: 8

Group type: COMPARATOR
Intervention: Mixed OL-HDF
Number of subjects: 8
Study: 21919543

Group type: EXPERIMENTAL
Intervention: Atorvastatin/metformin ER 10mg/500mg FDC
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atorvastatin 10mg (Lipitor®) and metformin 500mg (Glucophage® XR)
Number of subjects: 40
Study: 19883295

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (OTU) 80 mg twice daily
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg twice daily
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 17016711

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prednisolone (5 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12764904

Group type: EXPERIMENTAL
Intervention: TCM plus western medicine
Number of subjects: 79

Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 79
Study: 11734672

Group type: EXPERIMENTAL
Intervention: bezafibrate therapy (400 mg/day for 6 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: HTG patients
Number of subjects: 38
Study: 9722865

Group type: EXPERIMENTAL
Intervention: Submaximal exercise protocol (elbow flexions at two workloads)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Easier exercise protocol
Number of subjects: 16
Study: 8060578

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 to 40 mg twice daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Captopril (25 to 50 mg twice daily)
Number of subjects: 41
Study: 3051879

Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 30455336

Group type: EXPERIMENTAL
Intervention: Insulin correction factor adjusted by 50%
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Insulin correction factor adjusted by 100%
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Insulin correction factor adjusted by 150%
Number of subjects: 17

Group type: COMPARATOR
Intervention: Insulin correction factor adjusted by 0%
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Comparison between 100% and 50% corrections
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Comparison between 150% and 50% corrections
Number of subjects: 17
Study: 28315809

Group type: EXPERIMENTAL
Intervention: Exercise intervention (15 weeks)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Education control (15 weeks)
Number of subjects: 136
Study: 26581791

Group type: EXPERIMENTAL
Intervention: Vigorous intensity acute aerobic exercise
Number of subjects: 85

Group type: COMPARATOR
Intervention: Video watching control group
Number of subjects: 85
Study: 22901494

Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 423

Group type: COMPARATOR
Intervention: Telephone support
Number of subjects: 423
Study: 22141598

Group type: EXPERIMENTAL
Intervention: 77 Gy in 35 fractions to the entire prostate plus an additional integrated microboost to the macroscopic tumor of 95 Gy in 35 fractions
Number of subjects: 566

Group type: COMPARATOR
Intervention: 77 Gy in 35 fractions to the entire prostate
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 566
Study: 19911858

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prucalopride 4 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prucalopride (2 mg and 4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prucalopride
Number of subjects: 0
Study: 17064648

Group type: EXPERIMENTAL
Intervention: Allergoid SLIT for grass pollens (active treatment)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 33
Study: 15193479

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate, high‐dose recombinant human FSH, and a delayed, multidose GnRH antagonist
Number of subjects: 145

Group type: COMPARATOR
Intervention: Standard long protocol
Number of subjects: 145
Study: 10895837

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic glucose clamp technique (1.5 mU x kg(‐1) x min(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Euglycemia (5.01 +/‐ 0.02 mmol/l) maintained for 225 +/‐ 3 min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hypoglycemic condition (plasma glucose at 2.65 +/‐ 0.02 mmol/l for 90 min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Recovery phase after hypoglycemia
Number of subjects: 8
Study: 8873690

Group type: EXPERIMENTAL
Intervention: Bumetanide (0.005 to 0.10 mg/kg, single intravenous dose)
Number of subjects: 56
Study: 2054714

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (SCT) 200 IU per day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (SCT) 100 IU per day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (SCT) 50 IU per day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6656850

Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 30702412

Group type: EXPERIMENTAL
Intervention: Full‐contour lithium disilicate crown (LDS group)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Composite buildup and full‐contour lithium disilicate crown (P‐LDS group)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Endocrown (EC group)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Endodontic access cavity only (Control group)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Direct microhybrid composite restoration with glass fiber post (CP group)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Direct microhybrid composite (C group)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Glass fiber reinforced composite (GFRC group)
Number of subjects: 105
Study: 28981891

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24450390

Group type: EXPERIMENTAL
Intervention: Echocardiography measurements including MMode and 2D measurements of left ventricular (LV) and left atrial (LA) dimensions, LV tissue Doppler imaging (TDI), and tricuspid annular plane systolic excursion (TAPSE)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Echocardiography measurements
Number of subjects: 455

Group type: COMPARATOR
Intervention: T2D treatment
Number of subjects: 455
Study: 23834745

Group type: EXPERIMENTAL
Intervention: GPs using report cards and receiving personal clarification (n=17)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group GPs (n=9)
Number of subjects: 26

Group type: COMPARATOR
Intervention: GPs outside the study (n=200)
Number of subjects: 26
Study: 21714897

Group type: EXPERIMENTAL
Intervention: CRP/prealbumin ratio
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: CRP, albumin, prealbumin, cholesterol, CRP/albumin, CRP/cholesterol
Number of subjects: 155

Group type: COMPARATOR
Intervention: Healthy controls, maintenance hemodialysis, and peritoneal dialysis patients
Number of subjects: 155
Study: 19446968

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (placebo patch)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Denicotinized cigarettes
Number of subjects: 68
Study: 17046476

Group type: EXPERIMENTAL
Intervention: Continuous nebulized albuterol (15 mg) alone (A)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) (AI)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (AI)
Number of subjects: 62
Study: 14992872

Group type: EXPERIMENTAL
Intervention: On-pump surgery (Group A)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Off-pump surgery (Group B)
Number of subjects: 400